Cited by 158PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51

Open access

Kaplan, Alanna R., Gueble, Susan E., Liu, Yanfeng, Oeck, Sebastian, Kim, Hoon, Yun, Zhong, Glazer, Peter M.·2019·Science Translational Medicine

DOI 10.1126/scitranslmed.aav4508PMC PMC6626544

Open this paper in CoChat — free account

Abstract

Cediranib directly suppresses homology-directed DNA repair in tumor cells and confers synthetic lethal vulnerability to PARP inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aav4508

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,893
XRCC3 promotes homology-directed repair of DNA damage in mammalian cellsPreprint
Pierce, A. J., Johnson, R. D., Thompson, L. H., & Jasin, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2633 · Cited by 1,384
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Veroli, G. Y. D., Fornari, C., Wang, D. Y. Q., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 762
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 720
Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation
Chen, J., Martin, B. L., & Brautigan, D. L. (1992) · Science · doi:10.1126/science.1325671 · Cited by 601
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 592

Show all 34 references

Sorted by citations

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W. E., Klockow, J., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 877
Therapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 507
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance
Cui, C., Yang, J., Xiao, L., Liu, D., Fu, L., & Wang, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01180-y · Cited by 205
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Trenner, A., & Sartori, A. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01388 · Cited by 205
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
McMullen, M., Karakasis, K., Madariaga, A., & Oza, A. M. (2020) · Cancers · doi:10.3390/cancers12061607 · Cited by 199
PARP inhibitors: enhancing efficacy through rational combinations
Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. Y. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 183
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 162
The systemic treatment of recurrent ovarian cancer revisited
Baert, T., Ferrero, A., Sehouli, J., O’Donnell, D. M., González-Martı́n, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D. S. P., Querleu, D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.015 · Cited by 157
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Lheureux, S., Oaknin, A., Garg, S., Bruce, J. P., Madariaga, A., Dhani, N. C., Bowering, V. L., White, J., Accardi, S., Tan, D. S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4121 · Cited by 134
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Development of synthetic lethality in cancer: molecular and cellular classification
Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 123
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Chiappa, M., Guffanti, F., Bertoni, F., Colombo, I., & Damia, G. L. M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100744 · Cited by 113
Endometrial cancer: molecular classification and future treatments
Corr, B. R., Cosgrove, C. M., Spinosa, D., & Guntupalli, S. R. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000152 · Cited by 107
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Liu, J. F., Brady, M. F., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E. M., Cella, D. F., Tew, W. P., Cloven, N. G., Muller, C. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02011 · Cited by 99
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
Jain, A., Barge, A., & Parris, C. N. (2024) · Oncogene · doi:10.1038/s41388-024-03227-6 · Cited by 104
New approaches for targeting platinum-resistant ovarian cancer
McMullen, M., Madariaga, A., & Lheureux, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.013 · Cited by 88
Impact of hypoxia on DNA repair and genome integrity
Kaplan, A. R., & Glazer, P. M. (2019) · Mutagenesis · doi:10.1093/mutage/gez019 · Cited by 92
Self-citation
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
Lee, E. K., & Matulonis, U. A. (2020) · Cancers · doi:10.3390/cancers12082054 · Cited by 74
Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
Li, Y., Gao, Y., Zhang, X., Guo, H., & Gao, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119986 · Cited by 68
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Mahmood, R. D., Morgan, R. D., Edmondson, R. J., Clamp, A. R., & Jayson, G. C. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00933-8 · Cited by 68
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
Garg, V., & Oza, A. M. (2023) · Drugs · doi:10.1007/s40265-023-01934-0 · Cited by 71
Recent advancements of antiangiogenic combination therapies in ovarian cancer
An, D., Banerjee, S. N., & Lee, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102224 · Cited by 70
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
Colombo, N., Tomao, F., Panici, P. B., Nicoletto, M. O., Tognon, G., Bologna, A., Lissoni, A. A., DeCensi, A., Lapresa, M., Mancari, R., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.015 · Cited by 65
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
Veneris, J. T., Matulonis, U. A., Liu, J. F., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.021 · Cited by 62
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Bizzaro, F., Nerini, I. F., Taylor, M. A., Anastasia, A., Russo, M., Damia, G. L. M., Guffanti, F., Guana, F., Ostano, P., Minoli, L., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01196-x · Cited by 62
Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies
Klemba, A., Bodnar, L., Waś, H., Brodaczewska, K. K., Wcisło, G., Szczylik, C. A., & Kiéda, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249492 · Cited by 59
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Lee, J., Moore, R. G., Ghamande, S. A., Park, M. S., Diaz, J. P., Chapman, J. A., Kendrick, J. E., Slomovitz, B. M., Tewari, K. S., Lowe, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1733 · Cited by 53
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Zhu, Q., Dai, Q., Zhao, L., Zheng, C., Li, Q., Yuan, Z., Li, L., Xie, Z., Qiu, Z., Huang, W., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06303-z · Cited by 55
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Kim, J. W., McKay, R. R., Radke, M. R., Zhao, S., Taplin, M., Davis, N. B., Monk, P., Appleman, L. J., Lara, P. N., Vaishampayan, U. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02947 · Cited by 50
Self-citation
Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets
da Costa, A. A. B. A., & Baiocchi, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.016 · Cited by 48
Targeting DNA damage repair pathways in pancreas cancer
Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
Tao, L., Zhou, Y., Pan, X., Luo, Y., Qiu, J., Zhou, X., Chen, Z., Li, Y., Xu, L., Zhou, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42850-x · Cited by 44
Self-citation
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy
Gou, R., Dong, H., & Lin, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118434 · Cited by 42
Targeted therapies in gynaecological cancers
Crusz, S. M., & Miller, R. E. (2019) · Histopathology · doi:10.1111/his.14009 · Cited by 37
Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy
Jin, C., Yuan, M., Bu, H., & Jin, C. (2022) · Journal of Oncology · doi:10.1155/2022/4880355 · Cited by 38
Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease
Arend, R. C., Jackson-Fisher, A. J., Jacobs, I. A., Chou, J., & Monk, B. J. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1868937 · Cited by 35
PARP inhibitors for prostate cancer
Longoria, O., Beije, N., & de Bono, J. S. (2024) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.09.003 · Cited by 34
Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment
Shan, W., Yuan, J., Hu, Z., Jiang, J., Wang, Y., Loo, N., Fan, L., Tang, Z., Zhang, T., Xu, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107884 · Cited by 35
Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer
Zhang, N., Tian, Y., Zhou, L., Li, M., Chen, H., Song, S., Huan, X., Bao, X., Zhang, A., Miao, Z., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03475-4 · Cited by 37
Ovarian cancer targeted therapy: current landscape and future challenges
Wang, G., Yang, H., Wang, Y., & Qin, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1535235 · Cited by 39
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Elyashiv, O., Ledermann, J. A., Parmar, G., Farrelly, L., Counsell, N., Feeney, A., El-Khouly, F., Macdonald, I. A., Neto, A., Arthur-Darkwa, E., et al. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002073 · Cited by 32
PARP inhibitor combinations in prostate cancer
Pezaro, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919897537 · Cited by 34
Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy
Li, Y., Liu, Y., Zhang, D., Chen, J., Yang, G., Tang, P., Yang, C., Liu, J., Zhang, J., & Ouyang, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00640 · Cited by 31
Self-citation
Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
Wu, K., Liang, J., Shao, Y., Xiong, S.-C., Feng, S., & Li, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777663 · Cited by 31
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
Flynn, M. J., & Ledermann, J. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.13 · Cited by 31
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
Ledermann, J. A., Embleton-Thirsk, A., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H. W., Oza, A. M., Vaughan, M. M., Friedlander, M. L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100043 · Cited by 28
Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
Soung, Y. H., & Chung, J. (2023) · Biomolecules · doi:10.3390/biom13101480 · Cited by 27
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Nicum, S., McGregor, N., Austin, R., Collins, L., Dutton, S., McNeish, I. A., Glasspool, R. M., Hall, M., Roux, R. L., Michael, A., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02567-6 · Cited by 26
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Lee, J., Brady, M. F., Miller, A., Moore, R. G., MacKay, H. J., McNally, L. J., Lea, J. S., Street, D. G., Lheureux, S., McDonald, M. E., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00683 · Cited by 26
Targeting RECQL5 Functions, by a Small Molecule, Selectively Kills Breast Cancer in Vitro and in Vivo
Chakraborty, S., Dutta, K., Gupta, P., Das, A. D., Das, A., Ghosh, S. K., & Patro, B. S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01692 · Cited by 26
BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and ovarian cancer
Raimundo, L., Paterna, A., Calheiros, J., Ribeiro, J., Cardoso, D., Piga, I., Junqueira-Neto, S., Hegan, D. C., Glazer, P. M., Indraccolo, S., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15506 · Cited by 26
Self-citation
Pancreatic Cancer: BRCA Targeted Therapy and Beyond
Keane, F., O'Connor, C. A., Park, W., Seufferlein, T. T. W., & O'Reilly, E. M. (2023) · Cancers · doi:10.3390/cancers15112955 · Cited by 26
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Kanakkanthara, A., Hou, X., Ekstrom, T. L., Zanfagnin, V., Huehls, A. M., Kelly, R. L., Ding, H., Larson, M. C., Vasmatzis, G., Oberg, A. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0732 · Cited by 23
Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer
Huang, X., Li, X., Shan, W., Chen, Y., Zhu, Q., & Xia, B.-R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1131342 · Cited by 23
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer
Flippot, R., Patrikidou, A., Aldea, M. D., Colomba, É., Lavaud, P., Albiges, L. K., Naoun, N., Blanchard, P., Terlizzi, M., Garcia, C., et al. (2022) · Drugs · doi:10.1007/s40265-022-01703-5 · Cited by 22
Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancer
Singh, H. M., Bailey, P. J., Hübschmann, D., Berger, A. K., Neoptolemos, J. P., Jäger, D., Siveke, J. T., & Springfeld, C. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22932 · Cited by 22
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
Park, J., Lim, M. C., Lee, J. K., Jeong, D. H., Kim, S. I., Choi, M. C., Kim, B., & Lee, J. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e12 · Cited by 21
PARP inhibition in treatment of pancreatic cancer
Hammel, P. R., Zhang, C., Matile, J., Colle, E., Hadj-Naceur, I., Gagaille, M.-P., Bouattour, M., Cros, J. F., de Mestier, L., & Lamuraglia, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1820330 · Cited by 20
NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Rimel, B. J., Enserro, D. M., Bender, D., Jackson, C. G., Tan, A., Alluri, N., Borowsky, M. E., Moroney, J. W., Hendrickson, A. W., Backes, F. J., et al. (2023) · Cancer · doi:10.1002/cncr.35151 · Cited by 20
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
Mansouri, A., McGregor, N., Dunn, R., Dobbie, S. T., Holmes, J., Collins, L., & Nicum, S. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-041463 · Cited by 18
New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review
Satora, M., Kułak, K., Zaremba, B., Grunwald, A., Świechowska-Starek, P., & Tarkowski, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1416555 · Cited by 18
Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs
Nakai, H., & Matsumura, N. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02163-3 · Cited by 17
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Kim, J. W., Cardin, D. B., Vaishampayan, U. N., Kato, S., Grossman, S. R., Glazer, P. M., Shyr, Y., Ivy, S. P., & LoRusso, P. M. (2021) · The Oncologist · doi:10.1002/onco.13758 · Cited by 17
Self-citation
Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Li, L., Kumar, A. K., Hu, Z., & Guo, Z. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200224102309 · Cited by 17
Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair
Dow, J., Krysztofiak, A., Liu, Y., Colón-Ríos, D. A., Rogers, F. A., & Glazer, P. M. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0456 · Cited by 16
Self-citation
Therapeutic Application of PARP Inhibitors in Neuro-Oncology
Ning, J., & Wakimoto, H. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.004 · Cited by 16
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors
Lee, E. K., & Matulonis, U. A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773791 · Cited by 16
Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse
Washington, C. R., & Moore, K. N. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01337-6 · Cited by 15
PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction
Ray, U., Thirusangu, P., Jin, L., Xiao, Y., Pathoulas, C. L., Staub, J. K., Erskine, C. L., Dredge, K. S., Hammond, E., Block, M. S., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02785-5 · Cited by 15
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway
Iida, Y., Yanaihara, N., Yoshino, Y., Saito, M., Saito, R., Tabata, J., Kawabata, A., Takenaka, M., Chiba, N., & Okamoto, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1302850 · Cited by 15
Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer
Kulkarni, S., Gajjar, K. B., & Madhusudan, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414112 · Cited by 15
Strategies for the prevention or reversal of PARP inhibitor resistance
Mitri, Z. I., Goodyear, S. M., & Mills, G. B. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2393251 · Cited by 15
Vitamin D Modulates the Response of Patient-Derived Metastatic Melanoma Cells to Anticancer Drugs
Piotrowska, A., Zaucha, R., Król, O., & Zmijewski, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098037 · Cited by 15
LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder
Pei, L., Yan, D., He, Q., Kong, J., Yang, M., Ruan, H., Lin, Q., Huang, L., Huang, J., Lin, T., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00826-5 · Cited by 15
The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer
Khaddour, K., Fernandez, M. F., Khabibov, M., Гарифуллин, А., Dressler, D., Topchu, I., Patel, J. D., Weinberg, F. D., & Boumber, Y. (2022) · Cancers · doi:10.3390/cancers14215305 · Cited by 14
The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer
Murphy, A. D., Morgan, R. D., Clamp, A. R., & Jayson, G. C. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01605-5 · Cited by 14
Novel benzofuran-conjugated indolin-2-ones as anticancer agents; design, synthesis, biological assessments, and molecular modeling insights
Eldehna, W. M., Tawfik, H. O., Nafie, M. S., Kamaly, O. M. A., El-Hamaky, A. A., Hassab, M. A. E., Elsayed, Z. M., Elnaggar, Y. S. R., Al-Karmalawy, A. A., di Giacomo, V., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108494 · Cited by 13
The DNA damaging revolution
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103117 · Cited by 13
PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation
Muvaffak, A., & Coleman, K. G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380633 · Cited by 12
Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
Xiao, Y., Wu, Y., Wang, Q., Li, M., Deng, C., & Gu, X. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02056-8 · Cited by 12
Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report
Wu, C., Fan, M., & Hu, Y. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001160 · Cited by 12
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
Liu, X., Ge, Z., Yang, F., Contreras, A., Lee, S., White, J. B., Lu, Y., Labrie, M., Arun, B., Moulder, S. L., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00427-9 · Cited by 12
Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
Jin, N. Y., Xia, Y., & Gao, Q. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5476 · Cited by 12
Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair
Altwerger, G. H., Ghazarian, M., & Glazer, P. M. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.007 · Cited by 13
Self-citation
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley, C., Miller, R. E., Hollis, R. L., & Ledermann, J. A. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000660 · Cited by 11
Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance
Hinchcliff, E., Chelariu-Raicu, A., & Westin, S. N. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000678 · Cited by 12
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
Ivy, S. P., Kunos, C. A., Arnaldez, F. I., & Kohn, E. C. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1657403 · Cited by 11
Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells
Romaniuk-Drapała, A., Skupin-Mrugalska, P., Garbuzenko, O. B., Hatefi, A., & Minko, T. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03469-0 · Cited by 11
Strategic Combination Therapies for Ovarian Cancer
Li, X., Ng, A. S. N., Mak, V. C. Y., Chan, K. K. L., Cheung, A., & Cheung, L. W. T. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200511084007 · Cited by 11
Protein kinase inhibitors for the treatment of prostate cancer
Chau, V., Madan, R. A., & Aragon‐Ching, J. B. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1925250 · Cited by 12
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Hao, W., Rajendran, B. K., Cui, T., Sun, J., Yingchun, Z., Palaniyandi, T., & Selvam, M. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5447 · Cited by 10
Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective
Xiang, J., Li, J., Guo, Z., Wu, J., Ma, D., Xu, H., Shang, T., Pu, P., Cong, L., Zhou, R., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00908-0 · Cited by 11
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Slootbeek, P. H. J., Tolmeijer, S. H., Mehra, N., & Schalken, J. A. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2266482 · Cited by 12
Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials
Huang, D., Ke, L., Cui, H., Su, L., & Sun, F. (2024) · BMC Women s Health · doi:10.1186/s12905-023-02879-y · Cited by 10
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Liu, J. F., Xiong, N., Wenham, R. M., Hendrickson, A. E. W., Armstrong, D. K., Chan, N., O’Malley, D. M., Lee, J.-M., Penson, R. T., Cristea, M. C., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.05.002 · Cited by 10
Anti-angiogenic therapy in ovarian cancer: current situation & prospects
Liu, Y., Luo, Y., Cai, M., Shen, P., Li, J., Chen, H., Bao, W., & Zhu, Y. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_1160_19 · Cited by 10
Self-citation
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis
Staropoli, N., Ciliberto, D., Luciano, F., Napoli, C., Costa, M., Rossini, G., Arbitrio, M., Labanca, C., Riillo, C., Giudice, T. D., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104229 · Cited by 9
Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition
Rackear, M., Quijano, E., Ianniello, Z., Colón-Ríos, D. A., Krysztofiak, A., Abdullah, R., Liu, Y., Rogers, F. A., Ludwig, D. L., Dwivedi, R., et al. (2024) · Oncotarget · doi:10.18632/oncotarget.28651 · Cited by 9
Self-citation

Authors: Kaplan, A. R., Gueble, S. E., Liu, Y., Oeck, S., Kim, H., Yun, Z., & Glazer, P. M.
Affiliations: Yale University (US)
Corresponding author: Glazer, Peter M.
ORCID: Kaplan, Alanna R.
Gueble, Susan E.
Liu, Yanfeng
Oeck, Sebastian
Kim, Hoon
Yun, Zhong
Glazer, Peter M.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2019-05-15
Volume: 11
Issue: 492
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aav4508
PMC: PMC6626544
OpenAlex: W2946425279
Cited by: 158
References: 34
Citations by year: 2026: 14 · 2025: 15 · 2024: 21 · 2023: 23 · 2022: 17 · 2021: 29 · 2020: 31 · 2019: 8
FWCI: 8.86
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (R01ES005775, R35CA197574, R01CA178254, F30CA221065, T32GM007205)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: cediranib, homology-directed repair, BRCA1, BRCA2, RAD51, synthetic lethality, olaparib, DNA repair inhibition, PARP inhibitor combination, tumor xenografts, myelosuppression
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Tumor Hypoxia, Animals, DNA Repair, Female, Humans, Indoles, Mice, Nude, Quinazolines, Down-Regulation, Gene Expression Regulation, Neoplastic, Receptors, Platelet-Derived Growth Factor, BRCA1 Protein, Xenograft Model Antitumor Assays, BRCA2 Protein, Vascular Endothelial Growth Factor Receptor-2, Cell Line, Tumor, E2F4 Transcription Factor, Rad51 Recombinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks